Antecedent liver disease and drug toxicity

Journal of Hepatology

Volumn 31, Issue 6, 1999, Pages 1098-1105

  Schenker, Steven ^a   Martin, Ralston R ^a   Hoyumpa, Anastacio M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMIODARONE; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; BROMFENAC; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450; CYTOKINE; DRUG; ENDOTOXIN; GLUTATHIONE; METHOTREXATE; MORPHINE; NALTREXONE; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PERHEXILINE; PROSTAGLANDIN; PYRAZINAMIDE; TETRACYCLINE; VALPROIC ACID;

ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG SENSITIVITY; GENETICS; LIVER DISEASE; LIVER METABOLISM; LIVER TOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0032710519     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80326-2     Document Type: Article

References (53)

1. Zimmerman HJ, Maddrey WC. Toxic and drug induced hepatitis. Schiff L, Schiff ER. Diseases of the Liver, 7th ed, Vol 1, Chap 28. 1993;707-783 JB Lippincott, Philadelphia.
2. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Safety. 17:1997;47-73.
3. Greenblatt DJ, Koch-Weser J. Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program. Eur J Clin Pharmacol. 7:1974;259-262.
4. Branch RA. Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease? Hepatology. 7:1987;772-776.
5. Branch RA, Morgan MH, James J, Read AE. Intravenous administration of diazepam in patients with chronic liver disease. Gut. 17:1976;975-983.
6. Bakti G, Fisch HV, Karlaganis G, Minder G, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines - model experiments with triazolam. Hepatology. 7:1987;629-638.
7. Roberts MS, Rumble RH, Wanwimolruk S, Thomas D, Brooks PM. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol. 25:1983;253-261.
8. Gitlin N. Salicylate hepatotoxicity: the potential role of hypoalbuminemia. J Clin Gastroenterol. 2:1980;281.
9. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol. 126:(Suppl 1):1997;13-22.
10. Clive DM, Staff JS. Medical progress in renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 310:1984;563-572.
11. Rabinowitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 87:1992;1696-1704.
12. Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med. 80:1986;1093-1097.
13. Zimmerman HJ, Maddrey WC. Acetaminophen hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 22:1995;767-773.
14. Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol. Hepatology. 29:1988;1153-1157.
15. Mitchell JR, Follow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis: IV. Protective role of glutathione. J Pharmacol Exp Ther. 187:1973;211-217.
16. Colell A, Garcia-Ruiz C, Miranda M, Ardite E, Mari M, Morales A, et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology. 115:1998;1541-1551.
17. Chawla RK, Watson WH, Estin CE, Lee EY, Schmidt J, McClain CJ. S-adenosylmethionine deficiency and TNF-2 in lipopolysaccharide-induced hepatic injury. Am J Physiol. 275:1998;6125-6129.
18. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colett A. Mitochondrial glutathione: importance and transport. Sem Liver Dis. 18:1998;389-402.
19. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 272:1994;1845-1850.
20. Tsukamoto H, Horne W, Kamimura S, Niemela O, Pakkila S, Yia-Herttuala S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 96:1995;620-630.
21. Ikejima K, Enomoto N, Iimuro Y, Ikejima A, Fang D, Xu J, et al. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol. 274:1998;G669-G676.
22. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol. 26:(Suppl 1):1997;23-30.
23. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Chironzi G, et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med. 338:1998;286-290.
24. Neal EA, Meffin PJ, Gregory PB. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology. 77:1979;96-102.
25. Hoyumpa AM, Schenker S. Influence of liver disease on the disposition and elimination of drugs. Schiff L, Schiff ER. Diseases of the Liver. 1993;784-824 JB Lippincott Co, Philadelphia.
26. Secor JW, Schenker S. Drug metabolism in patients with liver disease. Adv Int Med. 33:1987;379-406.
27. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology. 13:1991;786-795.
28. Levy M, Caraco Y, Geisslinger G. Drug acetylation in liver disease. Clin Pharmacokinet. 34:1998;219-226.
29. Debinski HS, Lee CS, Danks JA, MacKenzie PI, Desmond PV. Localization of uridine 5′-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 108:1995;1464-1469.
30. Arns PA, Adedoyin A, DiBisceglie AM, Waggoner JG, Hoofnagle JH, Wilkinson GR, et al. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis. Clin Pharm Ther. 62:1997;527-537.
31. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 51:1992;229-238.
32. George J, Murray M, Byth K, Farrell CG. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 21:1995;120-128.
33. Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther. 33:1983;95-101.
34. Forrest JAM, Adriaenssens P, Finlayson NDC, Prescott LF. Paracetamol metabolism in chronic liver disease. Eur J Clin Pharmacol. 15:1979;427-431.
35. Howe D, Adriaenssens PI, Prescott LI. Paracetamol metabolism following overdosage: application of high performance liquid chromatography. J Pharm Pharmacol. 29:1997;235-237.
36. Davis M, Simmons CJ, Harrison NG, Williams R. Paracetamol overdosage in man. Relationship between pattern of urinary metabolites and severity of liver damage. Q J Med. 178:1976;181-191.
37. Bay M, Schenker S. Interactions between alcohol and other hepatotoxins. Hall P. Alcoholic Liver Disease, 2nd ed. Vol 16. 1995;260-278 Arnold E/Hoder & Stoughton, England.
38. Chien JY, Thummel KE, Slattery JT, Ro H, Nelson SD, Lown KS, et al. Ethanol increases risk of acetaminophen hepatotoxicity in healthy adults. Hepatology. 28:1998;257A.
39. Bedford TA, Rowbotham DJ. Cisapride. Drug interactions of clinical significance. Drug Safety. 15:1996;167-175.
40. Watkins PB. Drug metabolism by cytochrome P450 in the liver and small bowel. Gastroenterol Clin North Am. 21:1992;511-526.
41. Lewis JM, Schiff ER. Methotrexate-induced chronic liver injuries: guidelines. Am J Gastroenterol. 88:1988;1337-1345.
42. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 121:1994;252-258.
43. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 25:1984;1057-1064.
44. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther. 48:1990;120-129.
45. Farrell GC. Drug-induced acute hepatitis. Drug Induced Liver Disease, Chap 12. 1994;262-269 Churchill Livingstone, London.
46. Hoyumpa A, Schenker S. Drugs and the liver. Maddrey WC. Gastroenterology and Hepatology. The Comparison Visual Reference. 1996;6.1-6.22 Current Medicine, Philadelphia.
47. Farrell GC. Management of drug-induced liver disease. Drug Induced Liver Disease, Chap 8. 1994;163 Churchill Livingstone, London.
48. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Spler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 69:1975;289-302.
49. Liaw Y-F, Huang MJ, San KD, Li KL, Wu FF, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med. 118:1993;424-428.
50. Watkins PB, Zimmerman HJ, Knapp ME, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 271:1994;992-998.
51. Schenker S. Toxic and drug induced hepatitis. Hepatitis: Viral and Drug Induced. 1991;46-56 National Health Labs Inc, La Jolla, CA. (monograph).
52. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy. JAMA. 281:1999;1014-1015.
53. Leff DR, Leff AR. Tuberculosis control policies in major metropolitan health departments in the United States. Am J Respir Crit Care Med. 156:1997;1487-1494.